LL-37 is a natural antimicrobial peptide produced by the human immune system to fight bacteria, viruses, and fungi. It works by disrupting the membranes of harmful microbes while promoting wound healing and modulating inflammation. Research shows it offers strong broad-spectrum protection and supports tissue repair in various studies.

Minimum order quantity: one box (10 vials x 5 mg).

LL-37 research peptide USA

Metabolic research compounds are studied for their interactions with cellular energy metabolism pathways. This category includes both peptide-based and non-peptide molecules examined for their interactions with metabolic signaling cascades, substrate utilization, and lipid regulation at the molecular level.

Examples include 5-Amino-1MQ, a small-molecule NNMT inhibitor investigated for its interactions with NAD⁺ metabolism pathways and adipocyte signaling, as well as peptides such as AOD-9604 and MOTS-c, which have been examined in the context of mitochondrial pathways and metabolic gene expression. These compounds are of interest in research examining energy substrate regulation, lipid oxidation mechanisms, and cellular metabolic function.

Mitochondrial Function Peptides LL-37 research peptide USA

Mitochondrial function peptides are studied for their interactions with mitochondrial structure and bioenergetic pathways. Compounds such as SS-31 and MOTS-c are examined for their interactions with electron transport chain activity, oxidative phosphorylation mechanisms, and reactive oxygen species (ROS) signaling at the cellular level.

LL-37 research peptide USA

Somatotropic Peptides

Somatotropic peptides, also referred to as growth hormone secretagogues (GHS), are compounds studied for their interactions with the hypothalamic-pituitary axis and endogenous growth hormone secretion pathways. These compounds are typically classified into two categories: GHRH analogues (Growth Hormone-Releasing Hormone analogues) and GHRPs (Growth Hormone-Releasing Peptides), which act on distinct receptor pathways involved in GH pulse amplitude and frequency regulation.

GLP-1 receptor agonists are compounds studied for their interactions with glucagon-like peptide-1 receptors and downstream metabolic signaling pathways. Newer-generation compounds in this category also demonstrate activity at additional receptor targets including glucagon and amylin receptors, while some operate through entirely distinct mechanistic pathways independent of GLP-1 receptor activation.

LL-37 research peptide USA